Financial Reports

Regulatory

2025-05-16 | Quarterly Report Q1 2025: Positive Outcome of Orviglance FDA Meeting in Advance of the NDA Submission

Regulatory

2025-04-11 | Annual Report 2024: Orviglance Advances to Registration Phase after Successful Phase 3 Study Completion

Regulatory

2025-02-07 | Q4 and Full Year Report 2024: Completion of Full Study Report Reinforces Successful Outcomes of SPARKLE Phase 3 Study

Regulatory

2024-11-07 | Quarterly Report Q3: Successful Outcome from Rights Issue with SEK 105 Million Extends Runway Until Late 2025

Regulatory

2024-08-15 | Half-Year Report 2024: Orviglance Completes Clinical Development with Successful Phase 3 Study

Regulatory

2024-05-16 | Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study

Regulatory

2024-04-08 | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024

Regulatory

2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May

Regulatory

2023-11-08 | QUARTERLY REPORT Q3 2023: Re-evaluation of SPARKLE Phase 3 Study Images Progresses According to Plan

Regulatory

2023-08-18 | Half-Year report 2023: Re-evaluation required after intra-reader inconsistency in scoring of images from phase 3 study SPARKLE

Regulatory

2023-05-11 | QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completed

Regulatory

2023-04-13 | Correction: Ascelia Pharma publishes annual report for 2022

Regulatory

2023-04-13 | Ascelia Pharma publishes annual report for 2022

Regulatory

2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023.

Regulatory

2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission

Regulatory

2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study

Regulatory

2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals

Regulatory

2022-04-11 | Ascelia Pharma publishes Annual Report for 2021

Regulatory

2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent

Regulatory

2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration

Regulatory

2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level

Regulatory

2021-05-12 | Quarterly Report Q1 2021: US office opened in preparation of launch

Regulatory

2021-03-30 | Ascelia Pharma publishes Annual Report for 2020

Regulatory

2021-02-16 | Quarterly Report Q4 2020: Mangoral shows high diagnostic value in new study

Regulatory

2020-11-05 | Quarterly Report Q3-2020: Raised market estimate for Mangoral and preparing for market launch

Regulatory

2020-08-20 | Quarterly Report Q2-2020: First participant in the hepatic study

Regulatory

2020-05-13 | Interim Financial Report Q1-2020: First patient enrolled in Phase 3 study SPARKLE

Regulatory

2020-04-06 | Ascelia Pharma publishes Annual Report for the financial year 2019

Regulatory

2020-02-14 | 2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE

Regulatory

2019-10-14 | Ascelia Pharma publishes Annual Report for the financial year 2018/2019

Regulatory

2019-08-22 | Phase III study of Mangoral to start in H2-2019